Efficacy and safety of clopidogrel versus aspirin monotherapy in patients at high risk of subsequent cardiovascular event after percutaneous coronary intervention (SMART-CHOICE 3): a randomised, open-label, multicentre trial

Heart, Artery and Coronary Diseases

Outcomes after fractional flow reserve-guided percutaneous coronary intervention versus coronary artery bypass grafting (FAME 3): 5-year follow-up of a multicentre, open-label, randomised trial

Lancet

Fearon WF, Zimmermann FM, Ding VY, Takahashi K, Piroth Z, van Straten AHM, Szekely L, Davidavičius G, Kalinauskas G, Mansour S, Kharbanda R, Östlund-Papadogeorgos N, Aminian A, Oldroyd KG, Al-Attar N, Jagic N, Dambrink JE, Kala P, Angerås O, MacCarthy P, Wendler O, Casselman F, Witt N, Mavromatis K, Miner SES, Sarma J, Engstrøm T, Christiansen EH, Tonino PAL, Reardon MJ, Otsuki H, Kobayashi Y, Hlatky MA, Mahaffey KW, Desai M, Woo YJ, Yeung AC, Pijls NHJ, De Bruyne B

doi: 10.1016/S0140-6736(25)00505-7

Heart, Artery and Coronary DiseasesTherapy and Intervention

Aspirin versus Clopidogrel Monotherapy After Percutaneous Coronary Intervention: 1-Year Follow-up of the STOPDAPT-3 Trial

Eur Heart J

Watanabe H, Natsuaki M, Morimoto T, Yamamoto K, Obayashi Y, Nishikawa R, Kimura T, Ando K, Domei T, Suwa S, Ogita M, Isawa T, Takenaka H, Yamamoto T, Ishikawa T, Hisauchi I, Wakabayashi K, Onishi Y, Hibi K, Kawai K, Yoshida R, Suzuki H, Nakazawa G, Kusuyama T, Morishima I, Ono K, Kimura T

doi: 10.1093/eurheartj/ehae617

Thrombosis and Stroke

Plain versus drug balloon and stenting in severe ischaemia of the leg (BASIL-3): open label, three arm, randomised, multicentre, phase 3 trial

BMJ

Bradbury AW, Hall JA, Popplewell MA, Meecham L, Bate GR, Kelly L, Deeks JJ, Moakes CA, BASIL-3 Investigators

doi: 10.1136/bmj-2024-080881

RECOMMENDED

Cardiovascular Risk and DiseasesFurther Publications

Efficacy and Safety of Lerodalcibep in Patients With or at High Risk of Cardiovascular Disease: A Randomized Clinical Trial

★ 2 Recommended by Prof. Dr Isabella Sudano, Faculty Member

JAMA Cardiol

Klug EQ, Llerena S, Burgess LJ, Fourie N, Scott R, Vest J, Caldwell K, Kallend D, Stein EA, LIBERATE-HR Investigators

doi: 10.1001/jamacardio.2024.1659

Heart, Artery and Coronary DiseasesFurther Publications

Extended Clopidogrel Monotherapy vs DAPT in Patients With Acute Coronary Syndromes at High Ischemic and Bleeding Risk: The OPT-BIRISK Randomized Clinical Trial

JAMA Cardiol

Li Y, Li J, Wang B, Jing Q, Zeng Y, Hou A, Wang Z, Liu A, Zhang J, Zhang Y, Zhang P, Jiang D, Liu B, Fan J, Zhang J, Li L, Su G, Yang M, Jiang W, Qu P, Zeng H, Li L, Qiu M, Ru L, Chen S, Zhou Y, Qiao S, Stone GW, Angiolillo DJ, Han Y, OPT-BIRISK Investigators

doi: 10.1001/jamacardio.2024.0534

Heart, Artery and Coronary Diseases

De-escalation to ticagrelor monotherapy versus 12 months of dual antiplatelet therapy in patients with and without acute coronary syndromes: a systematic review and individual patient-level meta-analysis of randomised trials

Lancet

Valgimigli M, Hong SJ, Gragnano F, Chalkou K, Franzone A, da Costa BR, Baber U, Kim BK, Jang Y, Chen SL, Stone GW, Hahn JY, Windecker S, Gibson MC, Song YB, Ge Z, Vranckx P, Mehta S, Gwon HC, Lopes RD, Dangas GD, McFadden EP, Angiolillo DJ, Leonardi S, Heg D, Calabrò P, Jüni P, Mehran R, Hong MK, Single Versus Dual Antiplatelet Therapy (Sidney-4) collaborator group

doi: 10.1016/S0140-6736(24)01616-7

Thrombosis and StrokeTherapy and Intervention

Direct oral anticoagulants versus no anticoagulation for the prevention of stroke in survivors of intracerebral haemorrhage with atrial fibrillation (PRESTIGE-AF): a multicentre, open-label, randomised, phase 3 trial

Lancet

Veltkamp R, Korompoki E, Harvey KH, Harvey ER, Fießler C, Malzahn U, Rücker V, Montaner J, Caso V, Sibon I, Ringleb P, Halse O, Hügen K, Ullmann S, Schuhmann C, Todd GP, Haas K, Palà E, Debette S, Lachaize M, D'Aoust T, Enzinger C, Ropele S, Fandler-Höfler S, Haidegger M, Wang Y, Wafa HA, Cancelloni V, Mosconi MG, Lip GYH, Lane DA, Haefeli WE, Foerster KI, Wurmbach VS, Nielsen PB, Hajjar K, Müller P, Poli S, Purrucker J, Laible M, D'Anna L, Silva Y, de Torres Chacon R, Martínez-Sánchez P, Boulanger M, Norrving B, Paré G, Wachter R, Ntaios G, Wolfe CDA, Heuschmann PU, PRESTIGE-AF Consortium

doi: 10.1016/S0140-6736(25)00333-2

Cardiovascular Risk and Diseases

Bempedoic Acid Reduces the Risk of Major Adverse Cardiovascular Events Across Patient Subgroups

Heart Failure

Early integration of palliative care versus standard cardiac care for patients with heart failure (EPCHF): a multicentre, parallel, two-arm, open-label, randomised controlled trial

Lancet Healthy Longev

Balata M, Radbruch L, Hesse M, Westenfeld R, Neukirchen M, Pfister R, Batzler YN, Öztürk C, Kavsur R, Tiyerili V, Weltermann B, Pölsler R, Standl T, Nickenig G, Becher MU, Heart Failure Network Rhineland

doi: 10.1016/j.lanhl.2024.08.006

Related content

Outcomes after fractional flow reserve-guided percutaneous coronary intervention versus coronary artery bypass grafting (FAME 3): 5-year follow-up of a multicentre, open-label, randomised trial

Aspirin versus Clopidogrel Monotherapy After Percutaneous Coronary Intervention: 1-Year Follow-up of the STOPDAPT-3 Trial

Plain versus drug balloon and stenting in severe ischaemia of the leg (BASIL-3): open label, three arm, randomised, multicentre, phase 3 trial

Efficacy and Safety of Lerodalcibep in Patients With or at High Risk of Cardiovascular Disease: A Randomized Clinical Trial

Extended Clopidogrel Monotherapy vs DAPT in Patients With Acute Coronary Syndromes at High Ischemic and Bleeding Risk: The OPT-BIRISK Randomized Clinical Trial

De-escalation to ticagrelor monotherapy versus 12 months of dual antiplatelet therapy in patients with and without acute coronary syndromes: a systematic review and individual patient-level meta-analysis of randomised trials

Direct oral anticoagulants versus no anticoagulation for the prevention of stroke in survivors of intracerebral haemorrhage with atrial fibrillation (PRESTIGE-AF): a multicentre, open-label, randomised, phase 3 trial

Bempedoic Acid Reduces the Risk of Major Adverse Cardiovascular Events Across Patient Subgroups

Early integration of palliative care versus standard cardiac care for patients with heart failure (EPCHF): a multicentre, parallel, two-arm, open-label, randomised controlled trial